drugset / Trial / NCT00466102

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

NCT00466102

Phase 2 Unknown 130 enrolled GBG Forschungs GmbH Novartis · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine wether RAD001 can inhibit growth of tumour cells and/or stop the formation and activity of bone degrading osteoclasts.

Timeline

Start
2006-12
Primary completion
2010-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Everolimus Small molecule 10 mg Oral

Indications